Table 2.
Relationship between MLK3 mRNA expression and clinicopathologic variables of patients with gliomas.
| Variables | Number | MLK3 expression | X2 value | P value | ||
|---|---|---|---|---|---|---|
| High (%) | Low (%) | |||||
| IDH | Wildtype | 136 | 79 (58.1) | 57 (41.9) | 6.785 | 0.009** |
| Mutation | 150 | 64 (42.7) | 86 (57.3) | |||
| 1p/19q codeletion | Codel | 57 | 24 (42.1) | 33 (57.9) | 1.775 | 0.183 |
| Non-codel | 229 | 119 (52.0) | 110 (48.0) | |||
| MGMT promoter | Methylated | 147 | 73 (49.7) | 74 (50.3) | 0.014 | 0.906 |
| Unmethylated | 139 | 70 (50.4) | 69 (49.6) | |||
| EGFR | High | 143 | 58 (40.6) | 85 (59.4) | 10.196 | 0.001** |
| Low | 143 | 85 (59.4) | 58 (40.6) | |||
| MAPK8 | High | 143 | 45 (31.5) | 98 (68.5) | 39.287 | 0.000** |
| Low | 143 | 98 (68.5) | 45 (31.5) | |||
| MAPK9 | High | 143 | 53 (37.1) | 90 (62.9) | 19.147 | 0.000** |
| Low | 143 | 90 (62.9) | 53 (37.1) | |||
| MAPK10 | High | 143 | 56 (39.2) | 87 (60.8) | 13.441 | 0.000** |
| Low | 143 | 87 (60.8) | 56 (39.2) | |||
** P < 0.01.